NDAORALTABLET
Approved
Jun 1939
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Butisol Sodium (butabarbital sodium) is a barbiturate sedative-hypnotic agent approved in 1939 for oral use as a tablet. It is indicated for short-term management of insomnia and anxiety, acting as a central nervous system depressant. This is a legacy product with decades of clinical use in sedation and sleep disorder management.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating shrinking team and transition planning underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Butisol Sodium offers minimal career growth potential due to zero linked job openings and approaching loss of exclusivity. This is a legacy product in managed decline, suitable only for professionals seeking stable, short-term assignments in cost management or portfolio rationalization.
Brand ManagerField Sales Representative
Worked on BUTISOL SODIUM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.